Business Description
Phio Pharmaceuticals Corp
NAICS : 325412
SIC : 2834
ISIN : US74979C8082
Description
Phio Pharmaceuticals Corp is a clinical-stage biotechnology company whose proprietary INTASYL self-delivering RNAi technology platform is designed to make immune cells more effective in killing tumor cells. The Company is developing therapeutics that are designed to leverage INTASYL to precisely target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems.
Financial Strength
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 154 | |||||
| Equity-to-Asset | 0.84 | |||||
| Debt-to-Equity | 0.01 | |||||
| Debt-to-EBITDA | -0.01 | |||||
| Interest Coverage | No Debt | |||||
| Piotroski F-Score | 2/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 39.8 | |||||
| 3-Year EPS without NRI Growth Rate | 39.4 | |||||
| 3-Year FCF Growth Rate | 39.6 | |||||
| 3-Year Book Growth Rate | -57.6 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History |
|---|
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 6.38 | |||||
| Quick Ratio | 6.38 | |||||
| Cash Ratio | 5.87 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -98.1 | |||||
| Shareholder Yield % | 3.07 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -126.75 | |||||
| ROA % | -100.48 | |||||
| ROIC % | -6344.07 | |||||
| ROC (Joel Greenblatt) % | -14912.35 | |||||
| ROCE % | -127.9 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 0.51 | |||||
| Price-to-Tangible-Book | 0.51 | |||||
| EV-to-EBIT | 0.76 | |||||
| EV-to-EBITDA | 0.77 | |||||
| EV-to-Forward-Revenue | 0.16 | |||||
| EV-to-FCF | 0.7 | |||||
| Price-to-Net-Current-Asset-Value | 0.51 | |||||
| Price-to-Net-Cash | 0.56 | |||||
| Earnings Yield (Greenblatt) % | 131.58 | |||||
| FCF Yield % | -291.66 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Phio Pharmaceuticals Corp Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | |||
| EPS (TTM) (€) | 0 | ||
| Beta | 0 | ||
| Volatility % | 0 | ||
| 14-Day RSI | 0 | ||
| 14-Day ATR (€) | 0 | ||
| 20-Day SMA (€) | 5.8116 | ||
| 12-1 Month Momentum % | 0 | ||
| 52-Week Range (€) | 5.8116 - 5.8116 | ||
| Shares Outstanding (Mil) | 4.57 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Phio Pharmaceuticals Corp Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Phio Pharmaceuticals Corp Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Phio Pharmaceuticals Corp Frequently Asked Questions
What is Phio Pharmaceuticals Corp(FRA:44R3)'s stock price today?
The current price of FRA:44R3 is €5.81. The 52 week high of FRA:44R3 is €5.81 and 52 week low is €5.81.
When is next earnings date of Phio Pharmaceuticals Corp(FRA:44R3)?
The next earnings date of Phio Pharmaceuticals Corp(FRA:44R3) is .
Does Phio Pharmaceuticals Corp(FRA:44R3) pay dividends? If so, how much?
Phio Pharmaceuticals Corp(FRA:44R3) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers